Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mayo Clinic administered an investigational radioactive medicine to a patient with hepatocellular carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

A blood test could map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy, according to researchers at Mayo Clinic and Stanford Medicine. The test they developed could help guide treatment decisions across multiple cancer types and treatments.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login